Ind-Swift Laboratories Share Price Today (INDSWFTLAB)
TODAY IN ONE LINE
INDSWFTLAB fell 1.4% on light volume, in line with Nifty's -0.9% move, supported by recent strong earnings.
With a market cap of ₹2,034.15 Cr., it trades at a P/E of 50.25. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Ind-Swift Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 94.8% YoY
- ●Poor Capital ReturnsLow ROE of 3.9%
- ●Rising Receivables vs SalesReceivables grew 20.4% outpacing sales growth of -56.1%
Latest Ind-Swift Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
Ind-Swift Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Ind-Swift Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Ind-Swift Laboratories Limited trades at a P/E of 50.25× and P/B of 1.50×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Ind-Swift Laboratories Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Ind-Swift Laboratories Limited — derived from the live tape, not yesterday's close.
Ind-Swift Laboratories Limited last traded at ₹234.22 with an intraday range of ₹231–₹240.39 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹234.22| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 258.19 | +23.97 | +10.23% |
| R3 | 248.80 | +14.58 | +6.22% |
| R2 | 244.59 | +10.37 | +4.43% |
| R1 | 239.41 | +5.19 | +2.21% |
| PIVOT | 235.20 | 0.98 | 0.42% |
| CURRENT | 234.22 | — | — |
| S1 | 230.02 | -4.20 | -1.79% |
| S2 | 225.81 | -8.41 | -3.59% |
| S3 | 220.63 | -13.59 | -5.80% |
| S4 | 211.24 | -22.98 | -9.81% |
INDSWFTLAB is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹233.24–₹240.39
Trading Inside opening range
Ind-Swift Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Ind-Swift Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Ind-Swift Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,034.15 Cr. and reported EPS of ₹4.84.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 562 | 641 ▲ 14.2% |
| Sales Growth YoY %Derived | -56.15% | 14.17% |
| Other Income | 81 | 47 ▼ 42.3% |
| Total Income | 643 | 688 ▲ 7.0% |
| 288 | 282 ▼ 1.9% | |
| Gross ProfitDerived | 274 | 359 ▲ 31.1% |
| Gross Margin %Derived | 48.74% | 55.96% |
| 293 | 314 ▲ 7.0% | |
| EBITDA (Operating Profit)Derived | -19 | 45 ▲ 332.6% |
| OPM %Derived | -3.45% | 7.03% |
| 251 | 21 ▼ 91.6% | |
| Profit Before Tax (PBT) | 258 | 49 ▼ 81.0% |
| 7 | 8 ▲ 6.3% | |
| Effective Tax %Derived | 2.82% | 15.76% |
| Total Profit for Period | 250 | 41 ▼ 83.5% |
| Net Profit (Owner's PAT)Derived | 250 | 41 ▼ 83.5% |
| Net Profit Margin %Derived | 44.59% | 6.46% |
| PAT Growth YoY %Derived | -40.57% | -83.47% |
| Earnings Per Share (EPS ₹) | 41.32 | 4.77 ▼ 88.5% |
| Diluted Shares Outstanding (Cr) | 6 | 9 ▲ 43.3% |
| Share of Profit from Associates/JVs | -0 | 0 ▲ 289.0% |
| Other Comprehensive Income (Net of Tax) | 17 | -1 ▼ 105.1% |
| Total Expenses (incl. D&A & Interest) | 385 | 639 ▲ 65.9% |
| Material Cost % of RevenueDerived | 39.91% | 42.37% |
| Employee Cost % of RevenueDerived | 20.92% | 21.52% |
| Other Cost % of RevenueDerived | 31.27% | 27.41% |
| Interest Coverage (x)Derived | -15.03x | 10.31x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 765 | 757 ▼ 1.2% | 780 ▲ 3.0% | 891 ▲ 14.3% | 1,039 ▲ 16.5% | 1,207 ▲ 16.2% | 1,281 ▲ 6.1% | 562 ▼ 56.1% | 641 ▲ 14.2% | |
| Sales Growth YoY %Derived | — | -1.16% | 3.05% | 14.33% | 16.54% | 16.23% | 6.10% | -56.15% | 14.17% | |
| Other Income | 18 | 27 ▲ 49.0% | 33 ▲ 22.0% | 23 ▼ 32.0% | 43 ▲ 88.2% | 34 ▼ 21.6% | 45 ▲ 35.4% | 81 ▲ 79.4% | 47 ▼ 42.3% | |
| Total Income | 784 | 784 ▲ 0.0% | 813 ▲ 3.7% | 914 ▲ 12.4% | 1,081 ▲ 18.3% | 1,241 ▲ 14.7% | 1,326 ▲ 6.9% | 643 ▼ 51.5% | 688 ▲ 7.0% | |
394 | 398 ▲ 1.0% | 397 ▼ 0.2% | 451 ▲ 13.8% | 527 ▲ 16.6% | 656 ▲ 24.5% | 661 ▲ 0.9% | 288 ▼ 56.5% | 282 ▼ 1.9% | ||
| Gross ProfitDerived | 372 | 359 ▼ 3.5% | 383 ▲ 6.7% | 440 ▲ 14.9% | 512 ▲ 16.4% | 552 ▲ 7.7% | 619 ▲ 12.3% | 274 ▼ 55.8% | 359 ▲ 31.1% | |
| Gross Margin %Derived | 48.59% | 47.44% | 49.12% | 49.35% | 49.30% | 45.70% | 48.36% | 48.74% | 55.96% | |
238 | 223 ▼ 6.5% | 239 ▲ 7.1% | 257 ▲ 7.7% | 316 ▲ 22.8% | 323 ▲ 2.1% | 365 ▲ 13.2% | 293 ▼ 19.7% | 314 ▲ 7.0% | ||
| EBITDA (Operating Profit)Derived | 134 | 136 ▲ 1.9% | 144 ▲ 6.0% | 183 ▲ 26.6% | 196 ▲ 7.4% | 229 ▲ 16.7% | 254 ▲ 10.9% | -19 ▼ 107.6% | 45 ▲ 332.6% | |
| OPM %Derived | 17.46% | 18.01% | 18.52% | 20.51% | 18.91% | 18.98% | 19.85% | -3.45% | 7.03% | |
114 | 270 ▲ 138.1% | 198 ▼ 26.9% | 188 ▼ 5.1% | 227 ▲ 20.8% | 123 ▼ 45.8% | 491 ▲ 299.6% | 251 ▼ 49.0% | 21 ▼ 91.6% | ||
| Profit Before Tax (PBT) | 36 | 59 ▲ 64.7% | -20 ▼ 133.4% | 18 ▲ 191.1% | 13 ▼ 30.4% | 87 ▲ 590.4% | 582 ▲ 572.4% | 258 ▼ 55.7% | 49 ▼ 81.0% | |
14 | 21 ▲ 48.0% | 1 ▼ 93.2% | 21 ▲ 1392.9% | 15 ▼ 30.6% | 39 ▲ 163.5% | 151 ▲ 291.0% | 7 ▼ 95.2% | 8 ▲ 6.3% | ||
| Effective Tax %Derived | 38.99% | 35.03% | -7.17% | 117.48% | 117.15% | 44.72% | 26.00% | 2.82% | 15.76% | |
| Total Profit for Period | 22 | 38 ▲ 75.4% | -21 ▼ 155.1% | -3 ▲ 85.1% | -2 ▲ 31.7% | 48 ▲ 2314.8% | 421 ▲ 785.5% | 250 ▼ 40.6% | 41 ▼ 83.5% | |
| Net Profit (Owner's PAT)Derived | 22 | 38 ▲ 75.4% | -21 ▼ 155.1% | -3 ▲ 85.1% | -2 ▲ 31.7% | 48 ▲ 2314.8% | 421 ▲ 785.5% | 250 ▼ 40.6% | 41 ▼ 83.5% | |
| Net Profit Margin %Derived | 2.86% | 5.08% | -2.72% | -0.35% | -0.21% | 3.94% | 32.90% | 44.59% | 6.46% | |
| PAT Growth YoY %Derived | — | 75.37% | -155.12% | 85.15% | 31.71% | 2,314.83% | 785.47% | -40.57% | -83.47% | |
| Earnings Per Share (EPS ₹) | 4.84 | 8.08 ▲ 66.9% | -3.59 ▼ 144.4% | -0.53 ▲ 85.2% | -0.36 ▲ 32.1% | 8.06 ▲ 2338.9% | 71.33 ▲ 785.0% | 41.32 ▼ 42.1% | 4.77 ▼ 88.5% | |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 5.1% | 6 ▲ 24.2% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 2.6% | 9 ▲ 43.3% | |
| Share of Profit from Associates/JVs | — | — | — | — | — | -0 | — ▲ 100.0% | -0 | 0 ▲ 289.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | 0 ▲ 135.0% | 0 ▼ 88.2% | -2 ▼ 3010.0% | -0 ▲ 72.0% | 0 ▲ 175.1% | 0 ▲ 8.6% | 17 ▲ 4864.1% | -1 ▼ 105.1% | |
| Total Expenses (incl. D&A & Interest) | 748 | 725 ▼ 3.1% | 833 ▲ 14.9% | 896 ▲ 7.6% | 1,069 ▲ 19.3% | 1,154 ▲ 8.0% | 745 ▼ 35.5% | 385 ▼ 48.2% | 639 ▲ 65.9% | |
| Material Cost % of RevenueDerived | 48.40% | 54.98% | 52.47% | 50.93% | 54.39% | 54.46% | 46.77% | 39.91% | 42.37% | |
| Employee Cost % of RevenueDerived | 12.04% | 12.41% | 13.17% | 11.95% | 11.01% | 11.25% | 11.93% | 20.92% | 21.52% | |
| Other Cost % of RevenueDerived | 19.08% | 17.02% | 17.43% | 16.89% | 19.39% | 15.46% | 16.58% | 31.27% | 27.41% | |
| Interest Coverage (x)Derived | 1.67x | 0.39x | 0.51x | 0.95x | 0.68x | 1.86x | 3.93x | -15.03x | 10.31x |
Ind-Swift Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at Ind-Swift Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Ind-Swift Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Ind-Swift Laboratories Limited.
Our AI distills the core fundamental drivers supporting Ind-Swift Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Ind-Swift Laboratories Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Minimal debt-to-equity ratio of 0.0001x provides exceptional financial flexibility
Negative net debt of ₹4,113.98 Cr ensures substantial cash cushion for operations
Net profit margin of 41.4% TTM demonstrates strong pricing power in specialty APIs
FII ownership rose to 14.90%, signaling growing institutional confidence in stock
Stable promoter holding at 42.99% supports consistent governance and long-term vision
Key Risks.
Latest quarterly EPS declined 93.9% YoY despite revenue growth concerns
TTM EPS declined 94.8% YoY, indicating severe earnings quality deterioration
Operating margin negative at -1.55% quarterly signals core operational losses
ROE of 3.87% reflects poor capital efficiency versus peer benchmarks
Operating cash flow negative ₹40.19 Cr FY26 signals deteriorating cash generation
Flip Conditions.
Valuation risk. a P/E above 65 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Ind-Swift Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Ind-Swift Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Ind-Swift Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Ind-Swift Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Ind-Swift Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Ind-Swift Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Ind-Swift Laboratories Limited stood at 44.9% of traded volume, against a 20-day average of 40.3%.
Ind-Swift Laboratories announcements: results, concalls, ratings, M&A.
Filings Ind-Swift Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Ind-Swift Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 82 documents below.
Copy of Newspaper Publication
Submission of Newspaper Advertisement regarding dispatch of Notice of Extraordinary General Meeting ("EGM")
Shareholders meeting
Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on August 05, 2026
Copy of Newspaper Publication
Submission of Newspaper Publication in respect of Information Regarding Holding of the Extraordinary General Meeting of the Company through Video…
Outcome of Board Meeting
Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on July 10, 2026.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Ind-Swift Laboratories Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants)…
Investor decks & rating reports.
Ind-Swift Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Ind-Swift Laboratories has declared, sequenced by announce and record date.
Ind-Swift Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Ind-Swift Laboratories Limited: business, sector, key facts.
What Ind-Swift Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Ind-Swift Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: INDSWFTLAB, BSE: 532305.
Ind-Swift Laboratories Limited is a pharmaceutical company based in India that operates both domestically and internationally. Their core business centers around the development, manufacturing, and sale of active pharmaceutical ingredients (APIs), intermediates, and finished pharmaceutical formulations. This encompasses a wide range of therapeutic areas, demonstrating a significant breadth of product offerings.
The company's API portfolio covers a diverse spectrum of therapeutic applications. This includes areas such as antibiotics (macrolides), cardiovascular treatments, antihistamines, antidiabetics, antipsychotics, treatments for bone resorption disorders, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrheals/antiprotozoals, medications for alcohol abstinence, antineoplastics (anticancer agents), treatments for ADHD symptoms, hypercholesterolemia, antimigraine medications, and thrombocytopenia treatments. This extensive range highlights the company's commitment to addressing a broad array of medical needs.
Beyond APIs, Ind-Swift Laboratories also provides reference standards and impurities for a substantial list of pharmaceuticals. This includes key compounds across various therapeutic classes, supporting the quality control and analytical needs of other pharmaceutical manufacturers. The list of provided reference standards and impurities indicates a significant investment in analytical capabilities and a commitment to high-quality product development.
Further expanding its services, Ind-Swift Laboratories offers contract research and manufacturing services (CRAMS). This aspect of their business allows them to provide customized solutions and support to other pharmaceutical companies, leveraging their expertise in development and manufacturing to aid in the production of other companies’ drugs. This demonstrates a versatile business model that incorporates both internal product development and external partnerships.
In summary, Ind-Swift Laboratories Limited is a multifaceted pharmaceutical company with a strong focus on API manufacturing and a diversified portfolio of products and services. Their global reach, extensive range of therapeutic areas covered, and provision of CRAMS position them as a significant player in the Indian and international pharmaceutical landscape. The company's history, starting in 1995, suggests a considerable amount of experience and established processes within the industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Ind-Swift Laboratories Limited (INDSWFTLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Ind-Swift Laboratories Limited (INDSWFTLAB)?
The current share price of Ind-Swift Laboratories Limited (INDSWFTLAB) is ₹234.22. Today, the stock has declined by ₹3.38 (1.42%), trading in a range of ₹231 to ₹240.39. The stock opened at ₹239.8 with a trading volume of 3,71,291 shares.
02Is Ind-Swift Laboratories Limited stock a good investment for long-term?
Ind-Swift Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,034.15 crores, P/E ratio of 50.25, ROE of 3.87%, and ROCE of 4.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Ind-Swift Laboratories Limited stock?
The 52-week high price of Ind-Swift Laboratories Limited (INDSWFTLAB) is ₹248.45, while the 52-week low is ₹87.15. Currently trading at ₹234.22, the stock is 91.2% away from its 52-week low and 5.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Ind-Swift Laboratories Limited stock at the current price?
Whether to buy Ind-Swift Laboratories Limited stock at ₹234.22 depends on multiple factors. The stock is currently trading with a P/E ratio of 50.25 and P/B ratio of 1.50. Today's performance shows a loss of 1.42%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Ind-Swift Laboratories Limited and when is the next dividend?
Ind-Swift Laboratories Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹234.22, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Ind-Swift Laboratories Limited?
Ind-Swift Laboratories Limited's key financial metrics include: P/E Ratio: 50.25, P/B Ratio: 1.50, ROE: 3.87%, ROCE: 4.70%, Dividend Yield: 0.00%, EPS: ₹4.84, Book Value: ₹165.77, and Debt-to-Equity: 0.01. The company's market cap stands at ₹2,034.15 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Ind-Swift Laboratories Limited stock performing today in the market?
Ind-Swift Laboratories Limited stock opened at ₹239.8 and is currently trading at ₹234.22, showing a decline of ₹3.38 (1.42%). The intraday high is ₹240.39 and low is ₹231. The trading volume stands at 3,71,291 shares, indicating moderate market participation today.
08What is the P/E ratio of Ind-Swift Laboratories Limited and what does it indicate?
Ind-Swift Laboratories Limited has a Price-to-Earnings (P/E) ratio of 50.25, which means investors are willing to pay ₹50.25 for every ₹1 of earnings. With an EPS of ₹4.84, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Ind-Swift Laboratories Limited (INDSWFTLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.